Literature DB >> 22352446

Diabetic retinopathy: current and new treatment options.

Gian P Giuliari1.   

Abstract

Diabetes mellitus has become a major health concern worldwide and its incidence is projected to increase. Diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR) are considered the most sight-threatening ocular complications in these patients. Pivotal studies, such as the Early Treatment Diabetic Retinopathy Study (ETDRS) and the Diabetic Retinopathy Study (DRS), have established macular and pan-retinal laser as the gold-standard of treatment for these complications. The recent discovery of the vascular endothelial growth factor (VEGF) and its role in the development of proliferative disease, has led to a movement towards treating PDR and DME with anti-angiogenic medications alone or in conjunction with the gold-standard of care. Due to the severity of the diabetic ocular complications and the rising incidence of diabetes worldwide, it is important for the non-ophthalmologist care provider to be informed of the new treatments available for these conditions in an effort to better guide their patients. In this review, I will discuss the importance of these new methods of treatment as well as the significance of systemic glucose control, vitreous surgery and laser photocoagulation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22352446     DOI: 10.2174/157339912798829188

Source DB:  PubMed          Journal:  Curr Diabetes Rev        ISSN: 1573-3998


  15 in total

1.  Ligand-functionalized nanoparticles target endothelial cells in retinal capillaries after systemic application.

Authors:  Klaus Pollinger; Robert Hennig; Andreas Ohlmann; Rudolf Fuchshofer; Rebecca Wenzel; Miriam Breunig; Joerg Tessmar; Ernst R Tamm; Achim Goepferich
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-25       Impact factor: 11.205

2.  Angiogenic Factors and Cytokines in Diabetic Retinopathy.

Authors:  Steven F Abcouwer
Journal:  J Clin Cell Immunol       Date:  2013

Review 3.  Neuropeptides and diabetic retinopathy.

Authors:  Robert Gábriel
Journal:  Br J Clin Pharmacol       Date:  2013-05       Impact factor: 4.335

4.  Rodent Hyperglycemia-Induced Inner Retinal Deficits are Mirrored in Human Diabetes.

Authors:  Machelle T Pardue; Claire S Barnes; Moon K Kim; Moe H Aung; Raj Amarnath; Darin E Olson; Peter M Thulé
Journal:  Transl Vis Sci Technol       Date:  2014-06-19       Impact factor: 3.283

5.  Anti-angiogenic effect of metformin in mouse oxygen-induced retinopathy is mediated by reducing levels of the vascular endothelial growth factor receptor Flk-1.

Authors:  Soo Geun Joe; Young Hee Yoon; Jeong A Choi; Jae-Young Koh
Journal:  PLoS One       Date:  2015-03-18       Impact factor: 3.240

6.  Intraocular pressure rise is predictive of vision improvement after intravitreal triamcinolone acetonide for diabetic macular oedema: a retrospective analysis of data from a randomised controlled trial.

Authors:  Roderick F O'Day; Daniel Barthelmes; Meidong Zhu; Tien Y Wong; Ian L McAllister; Jennifer J Arnold; Mark C Gillies
Journal:  BMC Ophthalmol       Date:  2014-10-21       Impact factor: 2.209

7.  Identification of chemokines and growth factors in proliferative diabetic retinopathy vitreous.

Authors:  Ying Dai; Zhifeng Wu; Feng Wang; Zhengwei Zhang; Mengxi Yu
Journal:  Biomed Res Int       Date:  2014-10-27       Impact factor: 3.411

8.  Biomarkers for Diabetic Retinopathy - Could Endothelin 2 Be Part of the Answer?

Authors:  Nicolette Binz; Elizabeth P Rakoczy; Ireni S Ali Rahman; Nermina N Vagaja; Chooi-May Lai
Journal:  PLoS One       Date:  2016-08-02       Impact factor: 3.240

9.  PhTx3-4, a Spider Toxin Calcium Channel Blocker, Reduces NMDA-Induced Injury of the Retina.

Authors:  Nancy Scardua Binda; Charles Porto Petruceli Carayon; Rafael Mourão Agostini; Ana Cristina do Nascimento Pinheiro; Marta Nascimento Cordeiro; Marco Aurélio Romano Silva; Juliana Figueira Silva; Elizete Maria Rita Pereira; Claudio Antonio da Silva Junior; Célio José de Castro Junior; Andre Luiz Sena Guimarães; Marcus Vinicius Gomez
Journal:  Toxins (Basel)       Date:  2016-03-11       Impact factor: 4.546

10.  MicroRNA-126 contributes to Niaspan treatment induced vascular restoration after diabetic retinopathy.

Authors:  Yang Wang; Hua Yan
Journal:  Sci Rep       Date:  2016-05-26       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.